NASH

89bio Unveils Bullish Long-Term Data for NASH Candidate
89bio Unveils Bullish Long-Term Data for NASH Candidate
BioSpace
89Bio
NASH
clinical trials
pegozafermin
Flag link:
NASH on the Cusp: An Emerging Market Opportunity
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
Flag link:
Akero's stock sinks as midphase cirrhosis fail sparks flash NASH crash
Akero's stock sinks as midphase cirrhosis fail sparks flash NASH crash
Fierce Biotech
Akero Therapeutics
NASH
efruxifermin
clinical trials
Flag link:
Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs
Madrigal Pursues $500M Public Offering with NASH Market Up for Grabs
BioSpace
Madrigal Pharmaceuticals
NASH
resmetirom
Flag link:
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
Alfasigma To Acquire Intercept Pharma For $19 Per Share In Cash
RTT News
Intercept Pharma
M&A
Alfasigma
NASH
Flag link:
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Madrigal's stock shaken with CEO change up, as Sanofi's Sibold takes the reins
Fierce Biotech
Madrigal Pharmaceuticals
Pharma CEOs
Sanofi
Bill Sibold
NASH
Flag link:
Kriya, flush with funding, buys a gene therapy for NASH
Kriya, flush with funding, buys a gene therapy for NASH
BioPharma Dive
Kriya Therapeutics
gene therapy
NASH
M&A
Tramontane Therapeutics
Flag link:
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Eli Lilly infiltrates anti-obesity market as Phase III trial for retatrutide begins
Clinical Trials Arena
Eli Lilly
retatrutide
clinical trials
NASH
obesity
diabetes
type 2 diabetes
Flag link:
3 Biotechs Compete for the Same $108-Billion-Dollar Market
3 Biotechs Compete for the Same $108-Billion-Dollar Market
Motley Fool
NASH
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Prospective NASH market flips to over crowded as Big Pharma GLP-1s cast shadow over biotech breakthroughs
Fierce Biotech
NASH
Terns Pharmaceuticals
Madrigal Pharmaceuticals
Viking Therapeutics
Flag link:
Spotlight – Nash in 2023 and beyond
Spotlight – Nash in 2023 and beyond
EP Vantage
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Flag link:
Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space
Demise of Intercept’s NASH Program Highlights Safety Hurdles Facing the Space
BioSpace
Intercept Pharma
NASH
obeticholic acid
Flag link:
EASL 2023 – Biomarkers back a new NASH player
EASL 2023 – Biomarkers back a new NASH player
EP Vantage
NASH
89Bio
pefozafermin
Boston Pharmaceuticals
BOS-580
Flag link:
ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease
ADA says all diabetes patients should be screened for nonalcoholic fatty liver disease
Stat
ADA
diabetes
NASH
Flag link:
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Intercept restructures as Ocaliva's NASH hopes dashed again with FDA rejection
Fierce Pharma
Intercept Pharma
NASH
Ocaliva
obeticholic acid
FDA
Flag link:
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
Flag link:
Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide
Merck Gets FDA Fast Track for Efinopegdutide, Previews NASH Data Versus Novo’s Semaglutide
BioSpace
Merck
efinopegdutide
FDA
NASH
fast track
Flag link:
Rosa Biotech accelerates NASH pre-clinical trial in liver disease
Rosa Biotech accelerates NASH pre-clinical trial in liver disease
Biopharma Reporter
Rosa Biotech
bio-sensing
NASH
funding
Flag link:
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Stat
Akero Therapeutics
efruxifermin
NASH
Ozempic
Flag link:
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat
Hepion Claims Phase II NASH Victory Following Intercept’s Adcomm Defeat
BioSpace
Hepion Pharmaceuticals
clinical trials
NASH
rencofilstat
Flag link:

Pages